A. Hill

Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

E. Van Cutsem, M. Overman, S. Lonardi, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study

M. Overman, S. Lonardi, F. Gelsomino, 2024, Journal for ImmunoTherapy of Cancer.